Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.69 |
| ▸ | PHGDH | O43175 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8172365 | 0.84 | EPHX2 (0.71) | ERN1PHGDHHPGDAKR1C3EPHX2 | |
| SCHEMBL13952065 | 0.83 | HPGD (0.65) | ERN1PHGDHHPGDJAK2EPHX2 | |
| SCHEMBL12768143 | 0.82 | ERN1 (1.00) | ERN1PHGDHHPGDAKR1C3 | |
| SCHEMBL3637719 | 0.82 | PHGDH (0.56) | ERN1PHGDHHPGDAKR1C3EPHX2 | |
| SCHEMBL8160992 | 0.81 | HSD11B1 (0.54) | ERN1MEN1KMT2A | |
| SCHEMBL16592967 | 0.81 | ERN1 (0.60) | ERN1PHGDHHPGDAKR1C3EPHX2 | |
| SCHEMBL29119970 | 0.81 | ERN1 (0.54) | ERN1PHGDHHPGDJAK2AKR1C3 | |
| SCHEMBL10720943 | 0.80 | PHGDH (0.81) | PHGDHHPGDAKR1C3EPHX2KMT2A | |
| SCHEMBL149035 | 0.80 | TYK2 (0.53) | ERN1PHGDHHPGDPDE4BJAK2 | |
| SCHEMBL8150805 | 0.80 | HPGD (0.76) | PHGDHHPGDMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | ERN1 3534/4885PHGDH 787/4885HPGD 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.